Targeting immune cellular populations and transcription factors: unraveling the therapeutic potential of JQF for NAFLD
BackgroundNon-alcoholic fatty liver disease (NAFLD) constitutes the most prevalent chronic liver disease worldwide. Progression to non-alcoholic steatohepatitis (NASH), the immune cell reservoir within the liver undergoes remodeling, exacerbating liver…